Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Vaccine|June 25, 2010
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysisNicolas Van de Velde, Marc Brisson, Marie-Claude Boily
Sexually Transmitted Infections|October 7, 2010
Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11Marc Brisson, Nicolas Van de Velde, Marie-Claude Boily
American Journal of Epidemiology|February 6, 2007
Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertaintyNicolas Van de Velde, Marc Brisson, Marie-Claude Boily
Public Health Genomics|August 18, 2009
Economic evaluation of human papillomavirus vaccination in developed countriesMarc Brisson, Nicolas Van de Velde, Marie-Claude Boily
BMJ Open|December 2, 2016
Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov modelEmmanuelle Delgleize, Oscar Leeuwenkamp, Eleni Theodorou, et al.
BMC Infectious Diseases|May 5, 2022
Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infectionVasiliki Chounta, Sonya J Snedecor, Sterling Wu, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|August 22, 2007
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infectionMarc Brisson, Nicolas Van de Velde, Philippe De Wals, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|December 13, 2022
Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIVLouis S Matza, Timothy A Howell, Vasiliki Chounta, et al.
Vaccine|June 15, 2007
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in CanadaMarc Brisson, Nicolas Van de Velde, Philippe De Wals, et al.
MDM Policy & Practice|December 20, 2019
Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 CountriesChristophe Sauboin, Laure-Anne Van Bellinghen, Nicolas Van De Velde, et al.
Pageof 6